A Versatile Model of Microfluidic Perifusion System for the Evaluation of C-Peptide Secretion Profiles: Comparison Between Human Pancreatic Islets and HLSC-Derived Islet-Like Structures.
C-peptide
HLSC-ILS
T2DM
human pancreatic islets
microfluidic
obese
perifusion
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
07 Feb 2020
07 Feb 2020
Historique:
received:
29
01
2020
accepted:
05
02
2020
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
13
2
2020
Statut:
epublish
Résumé
A robust and easy-to-use tool for the ex vivo dynamic evaluation of pancreatic islet (PI) function is essential for further development of novel cell-based therapeutic approaches to treating diabetes. Here, we developed four different glucose perifusion protocols (GPPs) in a microfluidic perifusion system (MPS), based entirely on commercially available components. After validation, the GPPs were used to evaluate C-peptide secretion profiles of PIs derived from different donors (healthy, obese, and type 2 diabetic) and from human liver stem-cell-derived islet-like structures (HLSC-ILS). Using this device, we demonstrated that PIs derived from healthy donors displayed a physiological C-peptide secretion profile as characterized by the response to (a) different glucose concentrations, (b) consecutive pulses of high-glucose concentrations, (c) a glucose threshold ranging from 5-8 mM, and (d) a constant high-glucose perifusion in a biphasic manner. Moreover, we were able to detect a dysregulated secretion profile in PIs derived from both obese and type 2 diabetes mellitus (T2DM) donors. Finally, we also evaluated the kinetic secretion profiles of HLSC-ILS, demonstrating that, nonetheless, with a lower amplitude of secretion compared to PI derived from healthy donors, they were already glucose-responsive on day seven post-differentiation. In conclusion, we have provided evidence that our MPS is a versatile device and may represent a valuable tool to study insulin-producing cells in vitro.
Identifiants
pubmed: 32046184
pii: biomedicines8020026
doi: 10.3390/biomedicines8020026
pmc: PMC7168272
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unicyte (Oberdorf NW, Switzerland)
ID : Reg2019
Déclaration de conflit d'intérêts
Y.G. and C.T are employed by a commercial company (Unicyte AG) and contributed to the study as researcher. Y.G., V.N.-T., C.T., and G.C are named inventors in related patents. G.C. is a component of the scientific advisory board of Unicyte AG. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Stem Cell Rev Rep. 2019 Feb;15(1):93-111
pubmed: 30191384
Matrix Biol. 2020 Jan;85-86:205-220
pubmed: 31238092
Diabetes. 2005 Mar;54(3):727-35
pubmed: 15734849
J Clin Invest. 1996 Dec 15;98(12):2805-12
pubmed: 8981928
Annu Rev Anal Chem (Palo Alto Calif). 2016 Jun 12;9(1):249-69
pubmed: 27306310
Stem Cell Reports. 2019 Feb 12;12(2):351-365
pubmed: 30661993
Islets. 2011 Sep-Oct;3(5):284-90
pubmed: 21811103
Anal Chem. 2009 Aug 15;81(16):6837-42
pubmed: 19621896
Lab Chip. 2015 Feb 7;15(3):823-32
pubmed: 25474044
J Tissue Eng Regen Med. 2017 Mar;11(3):887-895
pubmed: 25619945
J Clin Invest. 1992 Oct;90(4):1263-8
pubmed: 1401063
Diabetes. 1972 Oct;21(10):987-98
pubmed: 4561331
Lab Chip. 2016 Feb 7;16(3):409-31
pubmed: 26732665
Diabetes. 1967 Jan;16(1):35-9
pubmed: 5333500
J Clin Invest. 2011 Jun;121(6):2118-25
pubmed: 21633180
Cell Transplant. 2008;16(10):1039-48
pubmed: 18351020
Diabetes. 2016 Feb;65(2):438-50
pubmed: 26307586
Physiol Rev. 1980 Apr;60(2):442-509
pubmed: 6247727
Endocrinology. 1968 Sep;83(3):572-84
pubmed: 4877098
Endocrinology. 1947 Feb;40(2):92-7
pubmed: 20286606
Lab Chip. 2017 Feb 28;17(5):772-781
pubmed: 28157238
ALTEX. 2010;27(2):105-13
pubmed: 20686743